Spermosens AB (publ) INTERIM REPORT JANUARY – SEPTEMBER 2025
RegulatoryAfter demonstrating the diagnostic value of JUNO-Checked earlier this year, we have now taken the next steps preparing for the market.
Read morePressreleases
Spermosens receives patent approval in Israel
RegulatorySpermosens AB (“Spermosens” or the “Company”) today announces that the patent “Biosensor for Male Infertility” (IL 280445) has been granted in Israel. The patent covers the company’s unique method for measuring sperm binding to the egg receptor JUNO, a critical biological interaction during fertilization that no existing test can evaluate.
Read moreSpermosens receives patent approval in Mexico
RegulatorySpermosens AB (“Spermosens” or the “Company”) today announces that the patent “Biosensor for Male Infertility” (MX/a/2021/002145) has been granted in Mexico. The patent covers the company’s unique method for measuring sperm binding to the egg, a critical biological interaction during fertilization that no existing test can evaluate.
Read moreSpermosens receives patent approval in Canada
RegulatorySpermosens AB (“Spermosens” or the “Company”) today announces that the patent “Biosensor for Male Infertility” (CA 3,109,529) has been granted in Canada. The patent covers the company’s unique method for measuring sperm binding to the egg receptor JUNO — a critical biological interaction during fertilization that no existing test can evaluate.
Read moreSpermosens AB (publ) INTERIM REPORT JANUARY – JUNE 2025
RegulatoryWe achieved a pivotal milestone during the second quarter, as strong clinical results clearly confirmed the diagnostic value of JUNO-Checked.
Read moreSpermosens provides status update following successful clinical study
Non-regulatorySpermosens AB (“Spermosens” or the “Company”) today provides a status update following the successful completion of its clinical study with the second-generation JUNO-Checked system and the full subscription of TO5 warrants. These milestones strengthen the Company’s position as it advances its diagnostic technology towards commercialization.
Read moreSpermosens announces outcome of exercise of warrants series TO 5
RegulatorySpermosens AB (publ) (“Spermosens” or the “Company”) today announces the outcome of the exercise of warrants of series TO 5 (the “Warrants”). A total of 467,740,274 shares were subscribed for through the exercise of Warrants, corresponding to an exercise rate of 100 percent. Spermosens will receive proceeds of approximately SEK 2.6 million before transaction costs.
Read moreSpermosens AB Announces Results from Annual General Meeting on 16 June 2025
RegulatorySpermosens AB ("Spermosens" or the "Company") today held its Annual General Meeting in Lund. The following resolutions were adopted: The Annual Report and Auditor’s Report for the financial year 2024 were presented. CEO Tore Duvold provided a summary of the Company’s operations and key developments over the past year. The meeting resolved to adopt the […]
Read moreChairman and CEO of Spermosens exercise TO5 warrants
RegulatorySpermosens AB (“Spermosens” or the “Company”) today announces that the Chairman of the Board, Ulrik Spork, and the CEO, Tore Duvold, have exercised their respective warrants of series TO5 for the subscription of new shares in the Company. Ulrik Spork has exercised 6,446,200 warrants, and Tore Duvold has exercised 5,750,000 warrants. The exercise of the […]
Read moreSpermosens concludes clinical study with statistically significant results supporting the diagnostic value of JUNO-Checked
RegulatorySpermosens AB (“Spermosens” or the “Company”) today announces positive topline results from its clinical study conducted at the Reproductive Medicine Center (RMC) in Malmö. The study was designed to validate the diagnostic value of the Company’s patented JUNO-Checked system and has now reached a successful conclusion. The results demonstrate a statistically significant correlation between the JUNO Score, a measurement of sperm binding to the JUNO receptor, and fertilization rate in IVF.
Read moreThe capital raise and issue announced in March 2025 is approved by Inspectorate of Strategic Products
RegulatoryOn March 4, 2025 Spermosens announced that the company has secured a SEK 10.8 million strategic investment through a directed issue. The investment is fulfilling the capital need until mid-2026. At the same time, Spermosens assessed that the issue had to be notified according to the Act (2023:560) on the review of foreign direct investments. A notification was sent to the Inspectorate of Strategic Products. After review, the authority today informed Spermosens that it leaves the notification without further action, which basically is the same as approving the issue.
Read moreLast day of trading in warrants series TO 5 in Spermosens is 12 June 2025
Regulatory12 June 2025 is the last day of trading in warrants of series TO 5 in Spermosens AB (publ) (“Spermosens” or the “Company”). Subscription of shares by exercise of warrants of series TO 5 is ongoing until 16 June 2025. One (1) warrant of series TO 5 entitles the holder to subscribe for one (1) new share in the Company at a subscription price of SEK 0.0055.
Read more
Spermosens Logotype
